Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 47.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 228,661 shares of the biopharmaceutical company’s stock after selling 202,424 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Gilead Sciences were worth $21,121,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in GILD. nVerses Capital LLC acquired a new stake in shares of Gilead Sciences during the third quarter worth about $25,000. Decker Retirement Planning Inc. purchased a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $29,000. Valued Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares during the period. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences during the second quarter worth $33,000. Finally, Friedenthal Financial acquired a new position in Gilead Sciences in the 3rd quarter valued at $50,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Wells Fargo & Company lifted their price objective on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Maxim Group downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Mizuho upped their price objective on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a research report on Wednesday, December 11th. Eleven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $97.96.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 25,590 shares of the business’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the sale, the insider now owns 99,599 shares in the company, valued at approximately $9,113,308.50. The trade was a 20.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 456,234 shares of company stock valued at $42,130,461. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $93.07 on Friday. The stock has a fifty day moving average price of $91.74 and a 200 day moving average price of $84.86. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90. The firm has a market capitalization of $115.99 billion, a P/E ratio of 1,034.11, a PEG ratio of 1.31 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences’s revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.29 earnings per share. Equities research analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 3.31%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s payout ratio is currently 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.